

Health Management International

Expansions continue to paint a rosy outlook

SINGAPORE | HEALTHCARE | FY18 RESULTS

- FY18 Revenue and Core PATMI were in line with our expectations.
- Higher outpatient loads and average bill sizes boosted earnings.
- Continues as a medical tourism hotspot with foreign patient load growing faster than local patient load.
- Proposed final dividend of RM1.0 Cent per share; total dividends of RM2.0 cents per share for FY18. (26% of FY18 Core EPS).
- Maintain BUY with unchanged DCF-derived TP of S\$0.83.

Results at a glance

(MYR mn)	FY17	FY18	YoY (%)	Comments
Hospital and other healthcare services	420.6	451.7	7.4%	Higher patient load and average bill sizes
Healthcare education and training	15.2	15.9	4.3%	
Revenue	435.8	467.6	7.3%	As above
Gross profit	143.8	165.8	15.3%	Higher revenue intensity and effective cost management. Gross margins +250bps to 35.5%
EBITDA	96.1	115.1	19.8%	EBITDA margins +250bps to 24.6%
NPAT	42.2	60.0	42.2%	Core NPAT +15.9% YoY
ΡΑΤΜΙ	20.6	60.6	194.4%	One-off impact of consolidation exercise, where 100% of net income now attributable to shareholders. Core PATMI +95.9% YoY

Source: Company, PSR

The Positives

- Patient volume and average bill sizes ramped up both hospitals' earnings. Mahkota (Mahkota Medical Centre) and Regency (Regency Specialist Hospital) saw a 3.7% YoY growth in total patient load to 461.8k in FY18. Foreign patient load grew faster than local patient load and accounted for 24% of the Group's patients. Outpatient load was the main driver, while inpatient load remained relatively flat because of competition from heavily subsidised Malaysian public healthcare as well as a trend towards shorter lengths of stay. Average bill size continued to grow with higher revenue intensity and increasingly complex surgeries. Average inpatient and outpatient bill size rose 5.6% and 9.0% YoY respectively.
- + **Day Surgery cases continue to lift margins.** Day Surgery is gaining traction as we continue to see bed occupancy rate trending downward (c.58% in 4Q18, vs c.62% in 4Q17) and higher average outpatient bill size. Note that the bed occupancy rate tracks overnight-stay and Day Surgery cases are billed under outpatient category. Total number of operational beds remained stable at 437.
- + Better than expected EBITDA margins improvement. EBITDA margin improved +250bps YoY to 24.6% for FY18, driven by Regency's margin (Regency is newer as compared to Mahkota, which is 25 years old) and effective cost management measures.



30 August 2018 **BUY (Maintained)** LAST CLOSE PRICE SGD 0.615 FORECAST DIV SGD 0.006 SGD 0.83 TARGET PRICE TOTAL RETURN 36.0% **COMPANY DATA BLOOMBERG CODE** HMISP O/S SHARES (MN): 837 MARKET CAP (USD mn / SGD mn): 377/515 52 - WK HI/LO (SGD) 0.73/0.56 3M Average Daily T/O (mn) 0.23 **MAJOR SHAREHOLDERS (%)** Nam See Investment Pte Ltd 35.6% 18.4% Maiu Medik (Malavsia) Sdn Bhd Kabouter Management LLC 6.0% Gan See Khem 13% Chin Wei Jia 1.2% **PRICE PERFORMANCE (%)** 1M T H змтн 1Y R COMPANY (5.5) (5.8) 87.7 STIRETURN 3.90 6.67 23.82

PRICE VS. STI





KEY FINANCIALS

Y/E Jun	F Y 16	F Y 17	F Y 18	FY 19 e
Revenue (RM mn)	398	436	468	537
EBITDA (RM mn)	85	96	115	133
NPAT (RM mn)	20	21	61	71
EPS (RM cts)	3.45	3.18	7.29	8.44
EPS (S cts)	1.15	1.01	2.46	2.84
PER, adj. (x)	29.3	65.7	25.0	21.6
P/BV, x	3.4	8.0	6.0	4.5
DPS (S cts)	0.25	0.32	0.67	0.57
Div Yield (%)	0.4%	0.5%	1.1%	0.9%
ROE (%)	12.6%	12.1%	28.8%	23.9%

Source: Bloomberg

VALUATION METHOD

DCF (WACC: 7.0%; terminal g: 1.8%)

Tin Min Ying (+65 6212 1853) Investment Analyst tinmy@phillip.com.sg

PhillipCapital

The Negative

Finance costs increased +57.2% or RM3.23mn YoY. Borrowings increased RM32.6mn due a RM103mn mortgage loan taken by the Group for its StarMed acquisition, offset by repayment of term loans during the year. Total debt spiked +19.9% YoY to RM196.4mn as at 30 Jun-18, but net gearing increased slightly to 0.55x from 0.52x a year ago. However, we think that the Group's higher leverage will be well contained by healthy operating cash flows to meet its debt obligation.

Outlook

We remain positive on the outlook of the upgrading and expansion plans in Mahkota and Regency and expect it to be on track to meet the growing demand.

- Mahkota has completed renovation works for Ward 9A and Paediatric Rehabilitation. But there will be continuous upgrading and refurbishing of older wards over the next 2 years. More clinical space for diagnostic radiology will be added.
- Regency's expansion plan is on track. The new extension block will more than double its existing capacity with additional - inpatient beds (mid-term target 380 beds, and eventually 500), clinical services, operating theatres and clinical suites. The hospital extension block is in process of approval, land preparation is ongoing and construction is expected to commence by end 2018. The extension is slated to commission in 2021.
- Both hospitals continue to develop their Centres of Excellence and recruit skilled subspecialists to broaden their service offerings especially in quality and safety.
- We do not expect any significant impact on Malaysia's Private Healthcare Facilities and Services Act arising from the change in government.
- StarMed (StarMed Specialist Centre) acquisition was completed in May 2018 and the Group now owns 62.5% of this one-stop ambulatory care centre in Singapore. StarMed has completed renovations and received licenses from the Ministry of Health's to operate. Main growth drivers for StarMed will be higher insurance-holding population, ageing population and medical tourism. StarMed is expected to incur gestation start-up losses from its operations and drag down margins for 2-3 years from its expected commencement in FY2019. We factored in RM1.6-2.2mn in EBIT loss p.a. for the first 3 years of operations.

Maintain BUY with unchanged DCF-derived TP of S\$0.83.

We maintain our view that HMI will benefit from the socioeconomic tailwinds arising from (i) public and private initiatives to improve infrastructure and regional connectivity; (ii) increasing domestic insurance take-up rate; (iii) favourable demographics; and (iv) cost competitive pricing compared to regional peers.

Balance Sheet

Financials

Income Statement

Y/E Jun, MYR mn	FY16	FY17	FY18	FY19e	FY20e
Revenue	398	436	468	537	590
EBITDA	85	96	115	133	148
Depreciation & Amortisation	(18)	(20)	(22)	(26)	(28)
EBIT	63	65	92	107	119
Share of results of assoc.	2	1	(0)	0	0
Net Finance Inc/(Exp)	(2)	(4)	(8)	(8)	(9)
Profit before tax	63	62	84	99	111
Taxation	(18)	(20)	(24)	(28)	(32)
NPAT before NCI, reported	45	42	60	71	79
NPAT before NCI, adjusted	48	54	62	71	79
Non-controlling interest	(26)	(22)	1	0	0
PATMI, reported	20	21	61	71	79
PATMI, adjusted	23	32	63	71	79

Per share data (MYR Cents)

Y/E Jun	FY16	FY17	FY18	FY19e	FY20e
EPS, reported	3.45	3.18	7.29	8.44	9.42
DPS	0.75	1.00	2.00	1.70	1.90
BVPS	29.58	26.06	30.34	40.53	51.65

Per share data (SGD Cents)

Y/E Jun	FY16	FY17	FY18	FY19e	FY20e
FX rate (SGD/MYR)	0.33	0.32	0.34	0.34	0.34
EPS, reported	1.15	1.01	2.46	2.84	3.17
DPS	0.25	0.32	0.67	0.57	0.64
BVPS	9.90	8.28	10.22	13.65	17.40

Cash Flow					
Y/E Jun, MYR mn	FY16	FY17	FY18	FY19e	FY20e
CFO					
Profit before tax	63	62	84	99	111
Adjustments	27	33	30	34	37
WC changes	4	(1)	(6)	4	2
Cash generated from ops	94	94	109	137	150
Others	(13)	(20)	(31)	(39)	(43)
Cashflow from ops	82	74	77	99	107
CFI					
CAPEX, net	(11)	(11)	(30)	(67)	(69)
Others	(11)	(216)	(12)	2	2
Cashflow from investments	(22)	(227)	(42)	(65)	(66)
CFF					
Share issuance, net	(1)	61	33	0	0
Loans, net of repayments	1	122	33	11	(31)
Dividends	0	(4)	(17)	(17)	(14)
Others	(25)	(26)	(103)	0	0
Cashflow from financing	(25)	153	(54)	(6)	(45)
Net change in cash	35	1	(18)	28	(5)
Effect of FX	1	1	(1)	(1)	(1)
CCE, end	79	77	59	120	144

Y/E Jun, MYR mn	FY16	FY17	FY18	FY19e	FY20e
ASSETS					
PPE	178	279	463	504	545
Others	50	0	0	0	0
Total non-current assets	228	279	463	505	545
Accounts receivables	57	45	49	47	54
Cash	79	77	59	120	144
Inventories	14	14	14	14	16
Others	4	3	7	7	7
Total current assets	155	138	129	188	222
Total Assets	383	418	592	693	767
LIABILITIES					
Accounts payables	79	68	110	112	124
Short term loans	27	72	89	89	69
Others	6	8	7	7	7
Total current liabilities	113	148	206	209	200
Long term loans	14	92	107	118	107
Others	24	9	30	30	30
Total non-current liabilities	38	101	137	148	137
Total Liabilities	151	249	343	356	337
EQUITY					
Non-controlling interests	62	0	(3)	(3)	(3)
Shareholder Equity	171	169	252	339	433

Valuation Ratios					
Y/E Jun	FY16	FY17	FY18	FY19e	FY20e
P/E (X), adj.	29.3	65.7	25.2	21.8	19.5
P/B (X)	3.4	8.0	6.1	4.5	3.6
EV/EBITDA (X), adj.	6.9	17.9	13.4	11.6	10.4
Dividend Yield (%)	0.4%	0.5%	1.1%	0.9%	1.0%
Growth & Margins (%)					
Growth					
Revenue	15.2%	9.5%	7.3%	14.8%	9.8%
EBITDA	15.4%	13.7%	19.8%	15.4%	11.2%
EBIT	18.7%	2.0%	41.8%	17.0%	11.5%
Net profit, adj.	-27.1%	40.3%	95.9%	12.5%	11.6%
Margins					
EBITDA margin	21.2%	22.1%	24.6%	24.7%	25.0%
EBIT margin	15.9%	14.8%	19.6%	19.9%	20.2%
Net profit, adj. margin	5.7%	7.4%	13.4%	13.2%	13.4%
Key Ratios					
ROE (%)	12.6%	12.1%	28.8%	23.9%	20.4%
ROA (%)	5.3%	5.1%	12.0%	11.0%	10.8%
Net Debt / (Cash)	(37)	87	137	87	32
Net Gearing (X)	Net Cash	51.6%	55.2%	25.9%	7.5%


Source: Company, Phillip Securities Research (Singapore) Estimates

*Forward multiples & yields based on current market price; historical multiples & yields based on historical market price.



HEALTH MANAGEMENT INTERNATIONAL RESULTS







Head of Research

Paul Chew - paulchewkl@phillip.com.sg

Banking and Finance Tin Min Ying – <u>tinmy@phillip.com.sg</u>

Transport | REITs (Industrial) Richard Leow - <u>richardleowwt@phillip.com.sg</u>

REITs (Commercial, Retail, Healthcare) | Property Tara Wong - <u>tarawongsj@phillip.com.sg</u>

> SINGAPORE Phillip Securities Pte Ltd Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel +65 6533 6001 Fax +65 6535 6631 Website: www.poems.com.sg

JAPAN Phillip Securities Japan, Ltd. 4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101 Fax +81-3 3666 6090 Website: www.phillip.co.jp

THAILAND Phillip Securities (Thailand) Public Co. Ltd 15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921 Website www.phillip.co.th

UNITED STATES Phillip Capital Inc 141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005 Website: www.phillipusa.com

INDIA

PhillipCapital (India) Private Limited No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969 Website: www.phillipcapital.in

> CAMBODIA Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306,Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia Tel: 855 (0) 7796 6151/855 (0) 1620 0769 Website: <u>www.phillipbank.com.kh</u> Contact Information (Singapore Research Team)

Oil & Gas | Energy Chen Guangzhi - <u>chengz@phillip.com.sg</u>

REITs (Commercial, Retail, Healthcare) | Property Dehong Tan - <u>tandh@phillip.com.sg</u>

Contact Information (Regional Member Companies) MALAYSIA Phillip Capital Management Sdn Bhd B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel +603 2162 8841 Fax +603 2166 5099

Website: <u>www.poems.com.my</u>

INDONESIA PT Phillip Securities Indonesia ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809 Website: www.phillip.co.id

FRANCE King & Shaxson Capital Limited 3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100 Fax +33-1 45636017 Website: www.kingandshaxson.com

AUSTRALIA Phillip Capital Limited Level 10, 330 Collins Street Melbourne, Victoria 3000, Australia Tel +61-03 8633 9803 Fax +61-03 8633 9899 Website: www.phillipcapital.com.au

TURKEY

PhillipCapital Menkul Degerler Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29 Website: www.phillipcapital.com.tr Marketing & Operations Mohamed Amiruddin - amiruddin@phillip.com.sg

Telco | Technology Alvin Chia - alvinchiawy@phillip.com.sg

Technical Analysis Jeremy Ng - jeremyngch@phillip.com.sg

China/HK Equity Zheng Jieyuan – <u>zhengjy@phillip.com.sg</u>

> HONG KONG Phillip Securities (HK) Ltd 11/F United Centre 95 Queensway Hong Kong Tel +852 2277 6600 Fax +852 2868 5307 Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940 Website: www.phillip.com.cn

UNITED KINGDOM King & Shaxson Capital Limited 6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950 Fax +44-20 7626 1757 Website: www.kingandshaxson.com

SRI LANKA Asha Phillip Securities Limited 2nd Floor, Lakshmans Building, No. 321, Galle Road, Colombo 03, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 Website: www.ashaphillip.net

DUBAI

Phillip Futures DMCC Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291 Dubai-UAE Tel: +971-4-3325052 / Fax: + 971-4-3328895



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
- (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.